Unfortunately there are no prospective data to guide management for cN1 prostate cancer treated with EBRT. The NCCN guidelines do not comment on the optimal duration of ADT in this setting. While 18 months may be considered for some patients with high risk cN0 prostate cancer as per the PCS IV trial...

When we prescribe an ADT duration, "18 months" is actually more like 24 months to forever, BTW . . . Relatively few studies describe testosterone recovery post ADT "expiration" but the few that I have seen, suggest that only a minority, something approaching 1/3rd, actually get testosterone back wit...

If the PSA is <0.5; androgen ablation is unnecessary. The intermittent  administration of one of the oral agents is effective.